Manuma Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
- Paid Up Capital ₹ 0.10 M
- Company Age 23 Year, 11 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 2.00 Cr
- Satisfied Charges ₹ 1.20 Cr
- Revenue Growth 6.51%
- Profit Growth 36.29%
- Ebitda 23.10%
- Net Worth 39.34%
- Total Assets -1.58%
About Manuma Pharmaceuticals
Manuma Pharmaceuticals Private Limited (MPPL) is a leading Private Limited Indian Non-Government Company incorporated in India on 27 February 2001 and has a history of 23 years and 11 months. Its registered office is in Jalgaon, Maharashtra, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹2.00 Cr. The company has closed loans amounting to ₹1.20 Cr, as per Ministry of Corporate Affairs (MCA) records.
Rajendra Patil and Leena Patil serve as directors at the Company.
Company Details
-
Location
Jalgaon, Maharashtra, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U24239MH2001PTC131028
-
Company No.
131028
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
27 Feb 2001
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Mumbai
Industry
Who are the key members and board of directors at Manuma Pharmaceuticals?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Rajendra Patil
|
Director | 06-Oct-2022 | Current |
|
Leena Patil
|
Director | 15-Jan-2016 | Current |
Financial Performance of Manuma Pharmaceuticals.
Manuma Pharmaceuticals Private Limited, for the financial year ended 2022, experienced modest growth in revenue, with a 6.51% increase. The company also saw a substantial improvement in profitability, with a 36.29% increase in profit. The company's net worth Soared by an impressive increase of 39.34%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Manuma Pharmaceuticals?
In 2022, Manuma Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹20.00 M
₹12.00 M
Charges Breakdown by Lending Institutions
- Others : 2.00 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 28 Nov 2021 | Others | ₹2.00 Cr | Open |
| 10 May 2018 | Others | ₹9.00 M | Satisfied |
| 16 Sep 2016 | Others | ₹3.00 M | Satisfied |
How Many Employees Work at Manuma Pharmaceuticals?
Unlock and access historical data on people associated with Manuma Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Manuma Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Manuma Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
